Oncopeptides hosted a Capital Markets Update on November 13, 2025, which was broadcasted live and recorded from Inderes studio in Stockholm.
The event provided shareholders and investors with a deeper understanding of the company’s strategic direction, growth plans, and expanding role in the evolving treatment landscape for multiple myeloma.
April 16, 2025
The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.
Read more
March 13, 2025
In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.
Read moreNovember 12, 2025
The NKEngage project, funded under the Eurostars program (Vinnova/Eureka), has successfully concluded after achieving its research goals.
Read moreNovember 11, 2025
Oncopeptides today announced that a panel of leading multiple myeloma experts has published clinical recommendations for the optimal use of melflufen (branded in Europe as Pepaxti) in Annals of Hematology.
Read moreNovember 3, 2025
Oncopeptides today announces that a collaborative study within the Eurostars funded project NKENGAGE has been accepted as a poster and will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in San Diego, California, between December 6–9, 2025.
Read more
November 5, 2025
Redeye’s analyst Richard Ramanius interviews Sofia regarding the Q3 report 2025.
Read moreOctober 29, 2025
Oncopeptides AB will publish the report for the third quarter 2025, at 08:00 CET on November 5, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on November 5 at 09:00 CET.
Read moreOctober 23, 2025
Oncopeptides will host a Capital Markets Update on November 13, 2025, from 09:00 to 12:00 CET, broadcast live from Inderes studio in Stockholm.
Read more
Released November 5, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Year-end Report 2025 will be published February 19, 2026
Press release - November 11, 2025
2026-01-19 - 2026-02-18
Other
2026-02-19
Report
2026-04-13 - 2026-05-12
Other
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.
Released April 28, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025
